ArticleNature2018
Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma.
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Mucosal immunity and vaccination strategies: current insights and future perspectives.Molecular biomedicine · 2025Review
- MYB Proto-Oncogene Like 2 identified as a biomarker for uterine corpus endometrial carcinoma: evidence from bioinformatics and clinical validation.Frontiers in oncology · 2025Article
- Unveiling immunogenic characteristics and neoantigens in endometrial cancer with POLE hotspot mutations for improved immunotherapy.Frontiers in immunology · 2025Article
- Revamping Hepatocellular Carcinoma Immunotherapy: The Advent of Microbial Neoantigen Vaccines.Vaccines · 2024Review
- OutSplice: A Novel Tool for the Identification of Tumor-Specific Alternative Splicing Events.BioMedInformatics · 2023Article
- Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.Signal transduction and targeted therapy · 2022Review
- Antitumor Peptide-Based Vaccine in the Limelight.Vaccines · 2022Review
- Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.Frontiers in immunology · 2021Article
- Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth.Translational oncology · 2020Article
- Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses.Frontiers in immunology · 2020Article
- Acquired resistance to cancer immunotherapy.Seminars in immunopathology · 2019Review
- A Review in Research Progress Concerning m6A Methylation and Immunoregulation.Frontiers in immunology · 2019Review
- Inactivation of DNA repair-prospects for boosting cancer immune surveillance.Genome medicine · 2018Article
- Cancer research in the era of immunogenomics.ESMO open · 2018Review
Corrections and comments
- Erratum for
Authors and funding
40 authors.
Funding
Abstract
This corrects the article DOI: 10.1038/nature22991.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.